Fig. 6: iDuo-MM CAR-NK cells maintain in vivo antitumor function in the absence of exogenous cytokine support.
NSG mice (n = 26) were engrafted with 2 × 105 luciferase-transduced MM.1S cells. Groups of mice (n = 4/group) received either no treatment or i.v. injections of 1 × 107 iDuo-MM CAR-NK cells thawed from cryopreservation on days 2, 9, and 16 post-tumor engraftment. Additional groups of mice were given i.v. injections of 2 × 106 primary anti-BMCA-CAR-T cells on day 2. Two independent batches of iDuo-MM CAR-NK cells were used, and all three treated groups were split and either given no exogenous cytokine support or supplemented with twice-weekly injections of IL-2 and IL-15. a Bioluminescence imaging of mice at days 2, 9, 16, and 23 post-tumor engraftments. b Graphical representation of bioluminescence data comparing mice treated with both batches of iDuo-MM CAR-NK cells to mice with tumor alone. c Graphical representation of bioluminescence data comparing mice treated with anti-BCMA-CAR-T cells to mice with tumor alone. d Graphical representation of bioluminescence data from all treatment and control groups. Statistical significance was determined by two-way ANOVA. Data are presented mean values ± SD. Source data are provided as a Source Data file.
